Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OsteoCorp Inc.

Latest From OsteoCorp Inc.

Building Bone: Next-Generation Osteoporosis Therapies

As Amgen gears up to launch osteoporosis candidate denosumab, a host of smaller players are working on what they see as the next-generation therapies: those that help build up new bone. Tough economic times across the board, plus the high development risks and costs associated with osteoporosis--a chronic, primary care condition--are making financing almost impossible for some.
BioPharmaceutical Business Strategies

OsteoCorp Inc.

The class of drugs called beta-blockers--long used for heart disease and migraines--also prompts an increase in bone mass. OsteoCorp will repurpose beta blockers to build bone in the treatment of conditions like bone cancer and osteoporosis.
BioPharmaceutical Business Strategies

Bone-Building Start-Ups

To some, the osteoporosis space may seem crowded with Big Pharma and Big Biotech drugs already on the market and more waiting in the wings. But it's a huge market with many unmet needs, offering start-ups an opportunity to develop even better, safer, more convenient drugs. In this issue we profile four emerging companies that are intent on creating novel bone-building, not just bone-preserving, drugs for the osteoporosis market.

Start-Up Previews (09/2008)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bone Building Start-Ups," features profiles of OsteoCorp, OsteoGeneX, Pradama, and Therosteon. Plus these Start-Ups Across Health Care: Aileron Therapeutics, Cohera Medical, CoLucid Pharmaceuticlas and Endogun Medical Systems.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • OsteoCorp Inc.
  • Senior Management
  • Charles Versaggi, PhD, Pres. & CEO
  • Contact Info
  • OsteoCorp Inc.
    Phone: (415) 806-6039
    9 Carolyn Ct.
    Mill Valley, CA 94941